PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML

Bibliographic Details
Main Authors:	Anand Patel, Laura Michaelis, Gary Schiller, Ronan Swords, Lawrence E. Morris, Luis A. Carvajal, Gordon Bray, Elizabeth A. Olek, Richard Cutler, Jorge Dimartino, Eytan Stein
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974380.14929.94

Similar Items

P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001)
by: E. M. Stein, et al.
Published: (2022-06-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
by: Andrea Duminuco, et al.
Published: (2022-09-01)

SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
by: Puissant, Alexandre, et al.
Published: (2017)

P454: VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING
by: C. Schmidt, et al.
Published: (2022-06-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY
by: D. Quintela, et al.
Published: (2022-06-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
by: You Na Ha, et al.
Published: (2020-01-01)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
by: Tristan E. Knight, et al.
Published: (2022-07-01)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
by: Katagiri S, et al.
Published: (2023-07-01)

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat <i>FLT3</i>-Mutated AML Patients
by: Matteo Molica, et al.
Published: (2023-05-01)

A Review of FLT3 Kinase Inhibitors in AML
by: Cristina Negotei, et al.
Published: (2023-10-01)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
by: Nicholas J. Short, et al.
Published: (2023-09-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)

An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation
by: Hiraku Ogata, et al.
Published: (2023-09-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
by: Andrius Žučenka, et al.
Published: (2023-08-01)

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
by: Shuai-Shuai Ge, et al.
Published: (2022-09-01)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
by: Michael Loschi, et al.
Published: (2021-05-01)

AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS
by: LBL Miranda, et al.
Published: (2023-10-01)

Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly
by: Masuho Saburi, et al.
Published: (2023-01-01)

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1
by: Daniel J.L. Coleman, et al.
Published: (2024-04-01)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
by: Xinhua Xiao, et al.
Published: (2023-11-01)

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
by: Bo-Reum Kim, et al.
Published: (2020-06-01)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
by: Maximilian Fleischmann, et al.
Published: (2021-11-01)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01)

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
by: Moo-Kon Song, et al.
Published: (2022-10-01)

Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation
by: Shintaro Izumi, et al.
Published: (2020-09-01)

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.
by: Federica Lessi, et al.
Published: (2023-08-01)

Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity
by: Ítalo Antônio Fernandes, et al.
Published: (2020-04-01)

Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia
by: Natsuki Hirose, et al.
Published: (2023-12-01)

PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia
by: Seong Hun Jang, et al.
Published: (2022-11-01)

P10.01 EFFECTS OF VEGFR-1 (FLT-1) INHIBITION DURING PREGNANCY ON THE UTERINE CIRCULATION OF THE MOUSE
by: G. Osol, et al.
Published: (2011-11-01)

Sweet syndrome induced by FLT3 inhibitors: case report and literature review
by: Linhui Yang, et al.
Published: (2024-12-01)

Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors
by: Hyo Jeong Kim, et al.
Published: (2020-11-01)

Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
by: Debora Capelli, et al.
Published: (2022-09-01)

FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
by: Blackmon A, et al.
Published: (2022-09-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01)

P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS
by: S. Shimony, et al.
Published: (2022-06-01)